Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitaxsentan Safety in Pulmonary Arterial Hypertension
NCT00811018Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Mar 2003
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 3 trial of sitaxsentan in pulmonary arterial hypertension (PAH), sponsored by Pfizer. Started Mar 2003; status: terminated.
02
Drugs
sitaxsentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT00811018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00811018.